Financial StabilityThe company has strengthened its cash position through additional financing, extending operations into the third quarter of 2025.
Product EfficacyD-PLEX100 showed a 38% reduction on the primary endpoint, which supports commercial uptake.
Regulatory ProgressD-PLEX100 has received Fast Track and Breakthrough designations, which supports a faster regulatory review process.